PharmaCyte Biotech announced increasing its stake in TNF Pharmaceuticals by $3 million to support TNF's recent license acquisition with LightSolver, Ltd.
The license is for a revolutionary processing accelerator using light for computation in cryptocurrency applications.
PharmaCyte Biotech maintains strong financial position with total assets exceeding $55 million as of April 30, 2025.
Strategic Investment
PharmaCyte Biotech increased stake in TNF Pharmaceuticals by $3 million to support the new technology acquisition.
LightSpeed Computing License
TNF Pharmaceuticals acquired a license with LightSolver for a breakthrough light-based computing platform for cryptocurrency applications.
Financial Strength
PharmaCyte Biotech remains well-capitalized with assets over $55 million, exploring further investment opportunities.
- The acquisition of the LightSolver license positions TNF Pharmaceuticals for innovative advancements in cryptocurrency mining and blockchain technology.
- PharmaCyte's increased stake demonstrates confidence in the potential of the new technology and its impact on the industry.
PharmaCyte Biotech's strategic investment in TNF Pharmaceuticals for the LightSolver license showcases commitment to cutting-edge technology and expansion in the cryptocurrency sector, reinforcing its position in the market.